ConductScience.org, home

Paper · 34529489

The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.

Martin TD and 8 others. Science, 2021. Cited by 128 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Papers, record 34529489. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34529489

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.
PubMed
Journal
Science
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
128
iCite
Relative citation ratio, by iCite
5.23
iCite
Revised in PubMed
2026-08-13
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Martin TDTimothy Dhttps://orcid.org/0000-0002-4870-3624
2Patel RSRupesh Shttps://orcid.org/0000-0001-5792-5969
3Cook DRDanielle R
4Choi MYMei Yuk
5Patil AAjinkyahttps://orcid.org/0000-0003-1080-1146
6Liang ACAnthony Chttps://orcid.org/0000-0002-8792-8260
7Li MZMamie Zhttps://orcid.org/0000-0002-7188-1330
8Haigis KMKevin M
9Elledge SJStephen Jhttps://orcid.org/0000-0001-7923-6283

Source PubMed

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinogenesisMajor topic
Gene SilencingMajor topic
Genes, Tumor SuppressorMajor topic
Immune EvasionMajor topic
Neoplasms, ExperimentalMajor topic
Animals
CRISPR-Cas Systems
Cell Line, Tumor
Chemokine CCL2
Female
GTP-Binding Protein alpha Subunits, G12-G13
Humans
Mammary Neoplasms, Experimental
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, SCID
Neoplasm Transplantation
Selection, Genetic
Tumor Microenvironment

Source PubMed

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
27144Cancer Research UKUnited KingdomPubMedPubMed
U01 CA199252NCI NIH HHSUnited StatesU01CA199252PubMed and NIHNIH RePORTER
Howard Hughes Medical InstituteUnited StatesPubMedPubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in34,529,483Opposing roles of the immune system in tumors.https://conductscience.org/library/papers/34529483PubMed
Comment in34,611,351Under pressure.https://conductscience.org/library/papers/34611351PubMed
Comment in35,027,544A new perspective on immune evasion: escaping immune surveillance by inactivating tumor suppressors.https://conductscience.org/library/papers/35027544PubMed

References72

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122,628,553Recurrent hemizygous deletions in cancers may optimize proliferative potential.Science2012https://conductscience.org/library/papers/22628553PubMed
230,837,996Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance.Front Immunol2019https://conductscience.org/library/papers/30837996PubMed
331,160,587Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma.Nat Commun2019https://conductscience.org/library/papers/31160587PubMed
429,719,257CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.Cell Rep2018https://conductscience.org/library/papers/29719257PubMed
520,844,553Harnessing transposons for cancer gene discovery.Nat Rev Cancer2010https://conductscience.org/library/papers/20844553PubMed
610,591,652Mouse models of tumor development in neurofibromatosis type 1.Science1999https://conductscience.org/library/papers/10591652PubMed
731,068,700Next-generation characterization of the Cancer Cell Line Encyclopedia.Nature2019https://conductscience.org/library/papers/31068700PubMed
828,196,594Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.Cancer Cell2017https://conductscience.org/library/papers/28196594PubMed
929,301,958A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.Science2018https://conductscience.org/library/papers/29301958PubMed
1031,253,869Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.Oncogene2019https://conductscience.org/library/papers/31253869PubMed

Cited by105

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 128 citations.

PMIDTitleJournalYearIn PapersSource
42,903,966Interactions between microbiota and innate immunity in tumor microenvironment: Novel insights into cancer progression and immunotherapy.Hlife2025https://conductscience.org/library/papers/42903966PubMed
42,829,916CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42829916PubMed
42,703,176An Insight into the Emerging Role of Extracellular Vesicle-derived Noncoding RNAs in Colorectal Cancer.Microrna2026https://conductscience.org/library/papers/42703176PubMed
42,685,085Changes in the transcriptome and synthetic lethal dependencies following KRAS mutant expression reveal profound tissue specificity.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/42685085PubMed
42,539,061EMT activates ER-to-Golgi trafficking through upregulation of REEP2 to promote lung cancer progression.Res Sq2026https://conductscience.org/library/papers/42539061PubMed
42,420,609Breast cancer driver genes found by screening chromosome aberrations in vivo.Nature2026https://conductscience.org/library/papers/42420609PubMed
42,297,823Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer.Nat Commun2026https://conductscience.org/library/papers/42297823PubMed
42,270,598CFTR-driven immune microenvironment reprogramming synergizes with anti-PD-L1 antibody in hepatocellular carcinoma.Cell Death Dis2026https://conductscience.org/library/papers/42270598PubMed
42,225,068Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens.Cell Rep Methods2026https://conductscience.org/library/papers/42225068PubMed
42,204,538The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention.Mol Cancer2026https://conductscience.org/library/papers/42204538PubMed

1 to 10 of 105

See all 105 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34529489

GET https://conductscience.org/api/papers/v1/34529489/references?page=2